ERBB2 and breast cancer: In the entire cohort, there were 24,057 patients (N = 14,966 ES-TNBC; N = 9091 HR+/HER2- BC) with a follow-up of ≥ 54 months (median = 79.5 months; IQR = 65.8–95.9 months) and a total of 1510 events.